Saturday 17 October 2026
Export BGLC’s income statement to Excel — free account
BioNexus Gene Lab Corp.
BGLC Basic Materials Specialty Chemicals
BioNexus Gene Lab Corp.’s revenue for fiscal 2025 (year ended December 2025) was $7.4 million, down 21.9% from fiscal 2024. In the quarter to June 2026, revenue fell 96.6%, EPS grew 64.7% and free cash flow grew 44.3%, each against the same quarter a year earlier.
1.20
0.02
−1.64%
Follow BGLC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.04 | 0.99 | 0.97 | 1.51 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.94) | 7.63 | (35.02) | (11.16) | |
P/B ratio |
1.44 | 0.85 | 0.64 | 0.61 | |
Price to Tangible BV |
1.44 | 0.85 | 0.64 | 0.61 | |
EV/Sales |
0.74 | 0.46 | 0.24 | 0.40 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.73) | (1.85) | (1.08) | (1.46) | |
EV/FCF |
(2.69) | (1.81) | (1.05) | (1.45) | |
Quick Ratio |
6.81 | 9.00 | 5.27 | 4.56 | |
Current Ratio |
8.30 | 10.46 | 6.52 | 6.08 | |
Net Debt/EBITDA |
4.53 | 4.12 | 8.17 | 15.98 | |
Debt/Assets |
0.00% | 0.00% | 0.52% | 0.52% | |
Debt/Equity |
0.00 | 0.00 | 0.01 | 0.01 | |
Asset Turnover |
1.02 | 0.75 | 0.57 | 0.34 | |
Operating CF/Net income |
1.75 | (0.93) | 0.27 | 1.47 | |
Capex/Depreciation |
(0.13) | (0.02) | (0.01) | (0.01) | |
Research and Development Expense of Revenue |
0.59% | 2.29% | 63.60% | 17.98% | |
Selling, General and Administrative Expense of Revenue |
39.21% | 209.07% | 1,668.42% | 438.98% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.49 | 0.66 | 0.82 | 0.85 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(24.35%) | (40.43%) | (69.16%) | (64.62%) | |
Free Cash Flow Yield |
(26.66%) | (25.57%) | (23.01%) | (18.11%) | |
Revenue per Share |
1.42 | 0.26 | 0.01 | 0.03 | |
Operating CF per Share |
(0.69) | 0.52 | (0.06) | (0.17) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.69) | 0.52 | (0.06) | (0.17) | |
Cash per Share |
1.61 | 2.18 | 1.64 | 1.46 | |
Shareholders Equity per Share |
3.79 | 4.64 | 3.35 | 3.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.79 | 4.64 | 3.35 | 3.22 | |
Free Cash Flow |
(1.24) | 0.96 | (0.15) | (0.42) | |
Working Capital |
4.95 | 4.93 | 4.40 | 4.13 | |
Capital Expenditures |
(0.01) | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
4.82 | 4.81 | 4.25 | 4.00 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.62 | 1.16 | 1.00 | 1.15 | |
Average Payables |
— | 0.52 | 0.75 | 0.60 | |
Average Inventory |
1.20 | 1.03 | 0.92 | 0.93 | |
Average Assets |
9.31 | 9.84 | 9.26 | 9.07 | |
Average Common Equity |
8.10 | 8.47 | 7.93 | 7.65 |
Columns are period end dates